Back to Agenda
Poster Session and Networking Reception
Speaker(s)
![Nancy Griffith, PhD](/_Images/member/Generic_Image_Missing-Profile.jpg)
The Effects of Chiral Control on the Pharmacologic Properties of Antisense Oligonucleotides
Nancy Griffith, PhD
Wave Life Sciences, United States
![Joe Harford, PhD](/_Images/member/Generic_Image_Missing-Profile.jpg)
A Targeted Nanocomplex that Actively Ferries Therapeutic Nucleic Acids Across the Blood-Brain Barrier
Joe Harford, PhD
SynerGene Therapeutics, Inc., United States
President & CEO
![Zhong Zhong](/_Images/member/Generic_Image_Missing-Profile.jpg)
DMD Exon 51 Skipping Efficiency and Dystrophin Protein Restoration Induced by WVE-210201: An Investigational Stereopure ASO
Zhong Zhong
Wave Life Sciences, United States
Vice President, Biology
![Petra Kos, PhD, MPharm](/_Images/member/Generic_Image_Missing-Profile.jpg)
miRNA-Loaded Lipid Nanoparticles for Ovarian Cancer Treatment
Petra Kos, PhD, MPharm
UT Southwestern Medical Center, United States
Postdoctoral Fellow
![Meena Meena, PhD](/_Images/member/Generic_Image_Missing-Profile.jpg)
Preclinical Studies of WVE-120101 and WVE-12010: Investigational Stereopure ASOs for Huntington’s Disease (HD)
Meena Meena, PhD
Wave Life Sciences, United States
Senior Director
![Hong Jiang, MS](/_Images/member/Generic_Image_Missing-Profile.jpg)
Impurity and Failure sequence Profile Change Due to Omission of the Capping Step in Synthesis of PS/PO Mixed Backbone ASOs
Hong Jiang, MS
Leal Therapeutics, United States
Scientist I
Quality Aspects of mRNA Drug Products: How Do We Control Identity, Purity, and Potency?
Silke Klick, PhD
AstraZeneca, Sweden
Regulatory Director CMC
![Ruiting Liang, PhD](/_Images/member/Generic_Image_Missing-Profile.jpg)
A Control Strategy for GMP Manufacturing of Antisense Oligonucleotides Based on a Liquid DS Platform
Ruiting Liang, PhD
Alkermes, United States
Senior Scientist
![Jennifer Freedman, PhD](/_Images/member/Generic_Image_Missing-Profile.jpg)
Development of a Novel Therapeutic Splice-Switching Oligonucleotide Targeting Race-Related Aggressive Prostate Cancer
Jennifer Freedman, PhD
Duke Cancer Institute, United States
Assistant Professor
Translatability of miR-29 PD Biomarkers from Preclinical Models to Mechanistic Proof of Concept in an MRG-201 Clinical Trial
Corrie L Gallant-Behm, PhD
Miragen Therapeutics, Inc., United States
Research Scientist III
![Marcin Kortylewski, PhD, MS](/_Images/member/Generic_Image_Missing-Profile.jpg)
Dual Function Oligonucleotide CpG-STAT3 Inhibitor for B-Cell Lymphoma Immunotherapy
Marcin Kortylewski, PhD, MS
City Of Hope, Beckman Research Institute, United States
Professor
![Mai Bailey Thayer, MS](/_Images/member/Generic_Image_Missing-Profile.jpg)
Ultra-Sensitive Locked Nucleic Acid Hybridization-Ligation ECL ELISA for Quantitative Measurement of siRNA
Mai Bailey Thayer, MS
Amgen Inc., United States
Senior Associate Scientist
Comparison of Subcutaneous and Intravenous Routes of Administration for Liver-Targeted RNAi Agents: Effect of PK-Modulating
Girish R Chopda, PhD
Dicerna Pharmaceuticals, United States
Associate Director, Nonclinical Development
![Josh Whisenand](/_Images/member/Generic_Image_Missing-Profile.jpg)
Innate Immune Focused Approaches to Maximize Messenger RNA Therapeutic Activity
Josh Whisenand
TriLink BioTechnologies, United States
![Brent Allen Dickinson](/_Images/member/Generic_Image_Missing-Profile.jpg)
Pharmacokinetic and Safety Data in Monkey and Human After IV Bolus Administration of MRG-106: An Inhibitor of miR-155
Brent Allen Dickinson
Miragen Therapeutics, United States
Manager, Pharmacokinetics
![Anita G Seto, PhD](/_Images/member/Generic_Image_Missing-Profile.jpg)
Phase 1 Trial Evaluating MRG-106: A Synthetic Inhibitor of microRNA-155 in CTCL Patients
Anita G Seto, PhD
miRagen Therapeutics, United States
Associate Director, Translational Sciences
Have an account?